• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , June 22

RANBAXY Laboratories Ltd has received tentative approval from the US Food and Drug Administration (FDA) to manufacture and market terbinafine hydrochloride tablets, 250 mg, indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).

Currently, Novartis sells the drug under the brand name Lamisil. The annual market for terbinafine hydrochloride tablets, 250 mg is $678.5 million.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
L&T plans 100 more RMC plants

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line